BioSig Completes Enrollment in the PURE EP 2.0 Clinical Study

Westport, CT, April 13, 2021 (GLOBE NEWSWIRE) -- 51 patients undergoing elective cardiac ablation treatments were enrolled in the trial at Mayo Clinic, Massachusetts General Hospital, and St. David’s Medical Center The trial is designed to demonstrate the quality and clinical value of the PURE EPTM signals when compared to conventional sources of cardiac signals. The Company expects to announce the study results in Q3 2021 BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the…